185 related articles for article (PubMed ID: 31707501)
1. The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy.
Khanal N; Ahmed SS; Kalra M; Miller TJ; Brames MJ; Stump TE; Monahan P; Hanna NH; Einhorn LH
Support Care Cancer; 2020 Jul; 28(7):3165-3170. PubMed ID: 31707501
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of hypogonadism determined by serum free testosterone level in Japanese testicular cancer survivors.
Kurobe M; Kawai K; Suetomi T; Iwamoto T; Waku N; Kawahara T; Kojima T; Joraku A; Miyazaki J; Nishiyama H
Int J Urol; 2018 May; 25(5):457-462. PubMed ID: 29478250
[TBL] [Abstract][Full Text] [Related]
3. Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study.
O'Carrigan B; Fournier M; Olver IN; Stockler MR; Whitford H; Toner GC; Thomson DB; Davis ID; Hanning F; Singhal N; Underhill C; Clingan P; McDonald A; Boland A; Grimison P;
Intern Med J; 2014 Aug; 44(8):813-7. PubMed ID: 25081047
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.
Willemse PM; Burggraaf J; Hamdy NA; Weijl NI; Vossen CY; van Wulften L; van Steijn-van Tol AQ; Rosendaal FR; Osanto S
Br J Cancer; 2013 Jul; 109(1):60-7. PubMed ID: 23660945
[TBL] [Abstract][Full Text] [Related]
5. Pearls and perils in the management of germ cell tumors.
Wei CX; Einhorn LH; Adra N
Curr Opin Oncol; 2021 May; 33(3):206-211. PubMed ID: 33577208
[TBL] [Abstract][Full Text] [Related]
6. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M; Dinh PC; Monahan PO; Fung C; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Sesso HD; Huddart R; Mushiroda T; Kubo M; Dolan ME; Einhorn LH; Fossa SD; Travis LB;
J Natl Compr Canc Netw; 2019 May; 17(5):459-468. PubMed ID: 31085753
[TBL] [Abstract][Full Text] [Related]
7. Re: Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.
Seftel A
J Urol; 2013 Nov; 190(5):1768. PubMed ID: 24120785
[No Abstract] [Full Text] [Related]
8. Prevalence of vertebral fractures independent of BMD and anticancer treatment in patients with testicular germ cell tumors.
Willemse PM; Hamdy NA; van Wulften L; van Steijn-van Tol AQ; Putter H; Osanto S
J Clin Endocrinol Metab; 2010 Nov; 95(11):4933-42. PubMed ID: 20702527
[TBL] [Abstract][Full Text] [Related]
9. Comment on 'Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'.
Singhera M; Huddart R
Br J Cancer; 2013 Oct; 109(9):2502-3. PubMed ID: 24045657
[No Abstract] [Full Text] [Related]
10. Reply: 'Comment on Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'.
Willemse PM; Burggraaf J; Hamdy NA; Osanto S
Br J Cancer; 2013 Oct; 109(9):2503-4. PubMed ID: 24045664
[No Abstract] [Full Text] [Related]
11. Hypogonadism and androgen deficiency symptoms in testicular cancer survivors.
Lackner JE; Märk I; Schatzl G; Marberger M; Kratzik C
Urology; 2007 Apr; 69(4):754-8. PubMed ID: 17445664
[TBL] [Abstract][Full Text] [Related]
12. Long-term sexual functioning in germ-cell tumor survivors.
Chovanec M; Vasilkova L; Petrikova L; Obertova J; Palacka P; Rejlekova K; Sycova-Mila Z; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M
BMC Cancer; 2020 Aug; 20(1):779. PubMed ID: 32819309
[TBL] [Abstract][Full Text] [Related]
13. Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older.
Feldman DR; Voss MH; Jacobsen EP; Jia X; Suarez JA; Turkula S; Sheinfeld J; Bosl GJ; Motzer RJ; Patil S
Cancer; 2013 Jul; 119(14):2574-81. PubMed ID: 23606402
[TBL] [Abstract][Full Text] [Related]
14. [High dose chemotherapy with autologous stem-cell support in germ cell tumors: The Instituto Português de Oncologia de Lisboa Francisco Gentil Series].
Brito M; Sanchez P; Velho S; Miranda N; Leal da Costa F; Ferreira I; Teixeira G; Guimarães A; Abecasis M; Passos Coelho JL
Acta Med Port; 2011; 24(4):533-44. PubMed ID: 22521011
[TBL] [Abstract][Full Text] [Related]
15. Does cisplatin-based chemotherapy effect on blood lipid levels of patients with germ cell testicular tumor in long-term follow-up?
Koc G; Divrik TR; Unlu N; Bulut V; Zorlu F
Int Urol Nephrol; 2011 Dec; 43(4):1095-100. PubMed ID: 21505757
[TBL] [Abstract][Full Text] [Related]
16. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for post-treatment hypogonadism in testicular cancer patients.
Eberhard J; Ståhl O; Cwikiel M; Cavallin-Ståhl E; Giwercman Y; Salmonson EC; Giwercman A
Eur J Endocrinol; 2008 Apr; 158(4):561-70. PubMed ID: 18362304
[TBL] [Abstract][Full Text] [Related]
18. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
[TBL] [Abstract][Full Text] [Related]
19. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
20. Androgen deficiency symptoms in testicular cancer survivors are associated with sexual problems but not with serum testosterone or therapy.
Lackner JE; Koller A; Schatzl G; Marberger M; Kratzik C
Urology; 2009 Oct; 74(4):825-9. PubMed ID: 19589582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
